{"id":182616,"date":"2024-02-13T09:24:31","date_gmt":"2024-02-13T15:24:31","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/02\/clinical-trial-shows-durvalumab-plus-ceralasertib-boosted-immune-response-in-lung-cancer-patients"},"modified":"2024-02-13T09:24:31","modified_gmt":"2024-02-13T15:24:31","slug":"clinical-trial-shows-durvalumab-plus-ceralasertib-boosted-immune-response-in-lung-cancer-patients","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/02\/clinical-trial-shows-durvalumab-plus-ceralasertib-boosted-immune-response-in-lung-cancer-patients","title":{"rendered":"Clinical trial shows durvalumab plus ceralasertib boosted immune response in lung cancer patients"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/clinical-trial-shows-durvalumab-plus-ceralasertib-boosted-immune-response-in-lung-cancer-patients2.jpg\"><\/a><\/p>\n<p>A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center.<\/p>\n<p>Results from the Phase II umbrella HUDSON study, published in <a href=\"https:\/\/doi.org\/10.1038\/s41591-024-02808-y\">Nature Medicine<\/a>, demonstrate that the anti PD-L1 antibody, durvalumab, coupled with the ATR inhibitor, ceralasertib, provides the greatest clinical benefit of four combinations evaluated.<\/p>\n<p>This pair had an objective response rate (ORR) of 13.9% compared to just 2.6% with the other tested combinations. Median progression-free survival (PFS) was 5.8 months versus 2.7 months for other combinations, while <a href=\"https:\/\/medicalxpress.com\/tags\/median+overall+survival\/\" rel=\"tag\" class=\"\">median overall survival<\/a> (OS) was 17.4 months versus 9.4 months. In patients with ATM alterations, which should sensitize tumors to ATR inhibitors, the ORR increased to 26.1%. Durvalumab-ceralasertib had a manageable safety profile.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center. Results from the Phase II umbrella HUDSON study, published in Nature [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-182616","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/182616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=182616"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/182616\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=182616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=182616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=182616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}